Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Trial (S5.005)

Agnies van Eeghen; Sarah M.L. Wilson; Elizabeth A. Thiele; Stevie Roszkowski; Maria Dunaway-Bryant; Kasia Wajer; Teresa Greco; Joanne Stevens; Lisa Moore-Ramdin; Petrus J. de Vries

doi:10.1212/wnl.0000000000215638

June 9, 2026Neurology

Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Trial (S5.005)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the effectiveness of adjunctive cannabidiol (CBD) on outcomes related to TAND in TSC patients.
Prespecified 6-month analysis of the EpiCom phase 3b/4 study (NCT05864846).
Participants received adjunctive cannabidiol (Epidiolex®).
Focus on outcomes related to TSC-associated seizures.
Initial findings indicate improvement in TAND outcomes post-CBD treatment.
Specific quantifiable effects were not detailed in the provided results.
Further analysis of long-term effects is ongoing.

Implication

Investigates TAND outcomes in participants with TSC after cannabidiol treatment, indicating potential benefits.

Abstract

This prespecified 6-month analysis of the ongoing EpiCom phase 3b/4 study (NCT05864846) investigated TAND outcomes after adjunctive cannabidiol (CBD; Epidiolex® [US]/Epidyolex® [EU], 100 mg/mL oral solution) initiation in participants with TSC-associated seizures.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Eeghen et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf34dfaef96ed7f055c13 https://doi.org/10.1212/wnl.0000000000215638

View Full Paper

Ask AI

Bookmark

Share

Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Trial (S5.005)

Key Points

Implication

Abstract

Discussion

Cite This Study

Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Trial (S5.005)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading